Eligibility
Start with the indication.
Weight-management eligibility generally begins with obesity, or overweight plus a weight-related condition, after a provider reviews the full picture.
Medical Weight Loss · Lincoln, NE
Tirzepatide & Zepbound in Lincoln, Nebraska
Clinical information from Revi's provider-led care team · Updated September 29, 2026
A local, provider-supervised approach to tirzepatide eligibility, safety, nutrition, and follow-up.
Tirzepatide and Zepbound in Lincoln, Nebraska
Tirzepatide is a once-weekly prescription medicine that activates both GIP and GLP-1 receptors. Zepbound® is the tirzepatide product approved for long-term weight reduction and maintenance in eligible adults, together with reduced-calorie nutrition and increased physical activity. Mounjaro® contains the same active ingredient but is approved for adults with type 2 diabetes. Product names describe different FDA-approved uses; they are not interchangeable marketing terms.
Revi provides local, provider-supervised medical weight loss in Lincoln. The first step is an evaluation of your health history, current medications, weight trajectory, metabolic markers, and goals. A prescription is never guaranteed.
Assessment
Labs and history matter.
Revi reviews metabolic health, thyroid patterns, medication history, contraindications, nutrition, and body-composition goals.
Follow-through
Response guides the plan.
Follow-up focuses on tolerability, nutrition, strength, hydration, side effects, and whether the treatment continues to make clinical sense.
Who May Be a Candidate?
The FDA-approved Zepbound indication includes adults with obesity, or adults with overweight and at least one weight-related condition. Body mass index is one part of the evaluation. Your provider also reviews prior weight-loss efforts, blood pressure, cholesterol, glucose patterns, sleep apnea, medications, and other health conditions.
Tirzepatide is not appropriate for everyone. Zepbound carries a boxed warning about thyroid C-cell tumors observed in rats and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Important warnings also cover severe gastrointestinal reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar with certain diabetes medicines, and aspiration risk around anesthesia or deep sedation.
What Your First Visit Covers
- Health and medication review. Bring your complete medication list and relevant personal and family history.
- Laboratory context. Revi reviews metabolic and other relevant markers rather than using weight alone.
- Eligibility and alternatives. Your provider explains whether an FDA-approved medication, another approach, or no medication is appropriate.
- Monitoring plan. If treatment begins, you receive instructions for follow-up, side effects, nutrition, hydration, and when to seek urgent care.
Zepbound vs. Semaglutide
Tirzepatide activates two receptors, GIP and GLP-1. Semaglutide activates GLP-1. That mechanistic difference does not make one medicine right for everyone. Medical history, approved indication, expected benefits, contraindications, tolerability, medication access, and patient preference all matter. See the semaglutide page or the broader medical weight loss program.
| Topic | Semaglutide | Tirzepatide |
|---|---|---|
| How it works | Activates GLP-1 receptors | Activates GIP and GLP-1 receptors |
| Weight-management product | Wegovy® | Zepbound® |
| Same ingredient, other approved use | Ozempic® (type 2 diabetes and specified cardiovascular and kidney uses) | Mounjaro® (adults with type 2 diabetes) |
| Given as | Prescription injection; schedule set by your provider | Once-weekly prescription injection |
| Who may qualify | Adults with obesity, or adults with overweight and at least one weight-related condition, after a full medical review | |
| Not appropriate with | A personal or family history of medullary thyroid carcinoma or MEN 2 | |
| Follow-up covers | Tolerability, nutrition, strength, hydration, side effects, and whether treatment continues to make sense | |
Product choice depends on the approved indication, your medical history, contraindications, tolerability, medication access and preferences. A prescription is never guaranteed. Talk to your provider.
FDA-Approved and Compounded GLP-1 Products
FDA-approved products have been reviewed for safety, effectiveness, and quality. Compounded drugs are not FDA approved. Federal rules permit compounding only in limited circumstances, and the regulatory landscape can change. If a compounded product is considered, the clinical team explains why, its current legal and clinical status, and how it differs from an FDA-approved medicine.
Read the official Zepbound prescribing information and Medication Guide.
Frequently Asked Questions
Both contain tirzepatide. Zepbound is approved for chronic weight management in eligible patients and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is approved to improve blood sugar control in adults with type 2 diabetes. Your provider determines whether an approved product and indication fit your case.
The FDA-approved indication includes adults with obesity or adults with overweight who also have at least one weight-related condition, together with reduced-calorie nutrition and increased physical activity. Eligibility and contraindications require a clinical evaluation.
Tirzepatide activates GIP and GLP-1 receptors. Semaglutide activates GLP-1 receptors. Product choice depends on approved indications, medical history, tolerability, access, and treatment goals.
Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, and reduced appetite. The prescribing information also includes important warnings and contraindications that your provider reviews before treatment.
No. Medication, laboratory, and follow-up costs vary. Revi reviews the expected cost before you begin a treatment plan.
Jeffrey A. Himmelberg, MD
Owner and Medical Director. Board-certified interventional radiologist with 20+ years of experience.
Read full bio →Kelly Thelen, APRN-NP
Nurse practitioner with more than 25 years in healthcare and hormone-care experience since 2009.
Read full bio →Educational information only. This page summarizes general information and does not replace the FDA-approved prescribing information or establish a provider-patient relationship. Treatment decisions require an individual medical evaluation. Individual results vary.